Abstract:We performed an ab initio next-generation risk assessment (NGRA) for a fragrance ingredient, benzyl salicylate (BSal), to demonstrate how cosmetic ingredients can be evaluated for systemic toxicity endpoints based on non-animal approaches. New approach methodologies (NAMs) used to predict the internal exposure included skin absorption assays, hepatocyte metabolism, and physiologically based pharmacokinetic (PBPK) modeling, and potential toxicodynamic effects were assessed using pharmacology profiling, ToxProfiler cell stress assay, transcriptomics in HepG2 and MCF-7 cells, ReproTracker developmental and reproductive toxicology (DART) assays, and cytotoxicity assays in human kidney cells. The outcome of the NGRA was compared to that of the traditional risk assessment approach based on animal data. The identification of the toxicologically critical entity was a critical step that directed the workflow and the selection of chemicals for PBPK modeling and testing in bioassays. The traditional risk assessment and NGRA identified salicylic acid (SA) as the "toxdriver." A deterministic PBPK model for a single-day application of 1.54 g face cream containing 0.5% BSal estimated the C max for BSal (1 nM) to be much lower than that of its major in vitro metabolite, SA (93.2 nM). Therefore, SA was tested using toxicodynamics bioassays. The lowest points of departure (PoDs) were obtained from the toxicogenomics assays. The interpretation of these results by two companies and methods were similar (SA only results in significant gene deregulation in HepG2 cells), but PoD differed (213 μM and 10.6 μM). A probabilistic PBPK model for repeated applications of the face cream estimated the highest C max of SA to be 630 nM. The resulting margins of internal exposure (MoIE) using the PoDs were 338 and 16, which were more conservative than those derived from external exposure and in vivo PoDs (margin of safety values were 9,705). In conclusion, both traditional and ab initio NGRA approaches concluded that the daily application of BSal in a cosmetic leave-on face cream at 0.5% is safe for humans. The processing and interpretation of toxicogenomics data can lead to different PoDs, which can subsequently affect the calculation of the MoIE. This case study supports the use of NAMs in a tiered NGRA ab initio approach.

Deriving a Point of Departure for Assessing the Skin Sensitization Risk of Wearable Device Constituents with In Vitro Methods

Deriving a Continuous Point of Departure for Skin Sensitization Risk Assessment Using a Bayesian Network Model

Predicting points of departure and potency categories for fragrance ingredients by integrating OECD in vitro models

Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the "2 out of 3" Defined Approach

GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) framework

Computational application of internationally harmonized defined approaches to skin sensitization: DASS App

Limitations and Modifications of Skin Sensitization NAMs for Testing Inorganic Nanomaterials

In Vitro Dendritic Cell-Based Test for Skin Sensitizers Identification and Potency Estimation

Skin Sensitisation Case Study: Comparison of Defined Approaches including OECD 497 Guidance

In Vitro Prediction of Skin-Sensitizing Potency Using the GARDskin Dose–Response Assay: A Simple Regression Approach

Next-generation risk assessment read-across case study: application of a 10-step framework to derive a safe concentration of daidzein in a body lotion

Development of an in Vitro Model to Simulate Migration of Organic Contaminants from Pad Products to Human Sweat and Enhance Dermal Exposure Risk Assessment

How to resolve inconclusive predictions from defined approaches for skin sensitisation in OECD Guideline No. 497

Assessment of skin sensitization potential of zinc oxide, aluminum oxide, manganese oxide, and copper oxide nanoparticles through the local lymph node assay: 5-bromo-deoxyuridine flow cytometry method

In vitro detection of contact allergens: development of an optimized protocol using human peripheral blood monocyte-derived dendritic cells

Increasing Accessibility of Bayesian Network-Based Defined Approaches for Skin Sensitisation Potency Assessment

Human relevance of in vivo and in vitro skin irritation tests for hazard classification of pesticides

Next generation risk assessment: an ab initio case study to assess the systemic safety of the cosmetic ingredient, benzyl salicylate, after dermal exposure

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment

Estimation of the Skin Sensitization Potential of Chemicals of the Acyl Domain Using DFT-Based Calculations

An epidermal equivalent assay for identification and ranking potency of contact sensitizers